CompletedNCT04578756
Long-term cariprazine safety in young people with schizophrenia, bipolarity, or autism
About this title
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
Read the official source — NCT04578756Medication studyAges 5–17United States
Understand this study
Who was this study for?
Listed age limits: 5 years to 17 years.
- Listed locations
- Dothan and 41 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: February 1, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 310
- Sponsor
- AbbVie
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 5 Years to 17 Years
- Official registry ID
- NCT04578756
- Official title
Show the full official title
A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Dothan, United States · Bentonville, United States · Anaheim, United States
33 more locations
- Long Beach, United States
- Orange, United States
- Rancho Cucamonga, United States
- San Diego, United States
- Upland, United States
- Doral, United States
- Gainesville, United States
- Hialeah, United States
- Homestead, United States
- Lake Mary, United States
- Miami, United States
- Miami Springs, United States
- Orlando, United States
- Tamarac, United States
- Atlanta, United States
- Decatur, United States
- Dunwoody, United States
- Hoffman Estates, United States
- Irvington, United States
- Buffalo, United States
- Kinston, United States
- Avon Lake, United States
- Cincinnati, United States
- West Chester, United States
- Oklahoma City, United States
- Austin, United States
- Dallas, United States
- Houston, United States
- Plano, United States
- The Woodlands, United States
- Everett, United States
- Caguas, Puerto Rico
- San Juan, Puerto Rico
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AbbVie.
Did this study involve medication?
Yes. The study involved medication, including Cariprazine Flexible Dose.
Who was this study for?
Listed age limits: 5 years to 17 years.
